Dr. Myung-Chul Lee appointed as the new Chairman of Institut Pasteur Korea 

- Key player in the advancement of Korea’s science and technology with leadership
spanning research, medical, and academic sectors -


 

On April 15, Institut Pasteur Korea (CEO Dr. Youngmee Jee) announced that Dr. Myung-Chul Lee, former Chairman of the Korean Academy of Science and Technology (KAST), has been appointed as the new Chairman of the IPK Board of Directors. 

 

Chairman Myung-Chul Lee has greatly contributed to the advancement of Korea’s science and technology with his leadership spanning research, medical, and academic sectors, and has also pioneered nuclear medicine in the country. 

During his service as the President and Chairman of KAST, Chairman Lee reinforced the institution’s domestic and international standing by expanding KAST’s role in representing national science and technology. As the Chairman of the Korea Drug Development Fund (KDDF), he was at the forefront of establishing a support system covering the entire process of drug development. 

Moreover, serving as a member of the National Safety and Security Commission of the Prime Minister’s Office and the Vice-Chairperson of the Presidential Advisory Council on Science and Technology, Chairman Lee provided advice on policies in the medical, science, and technology fields and contributed to system improvement. 

After graduating from Seoul National University College of Medicine, Chairman Lee served as a professor in nuclear medicine at the Seoul National University Hospital, President of the World Federation of Nuclear Medicine and Biology, and President of the World Council for Isotopes. By introducing the nuclear medicine medical specialist system in 1990, he enabled Korea’s nuclear medicine to progress to a global level. 

Regarding his appointment as the Chairman of IPK, he revealed, “I will do my best to support Dr. Youngmee Jee in strengthening IPK as a strategic foundation for national infectious disease response and hub of the Asia-Pacific regional research network by advancing basic and translational research capacity and global partnership that IPK possesses.”